Gewinn- und Verlustrechnung von Prestige Consumer Healthcare Inc.

Prestige Brand Holdings is recalling 39,060 bottles of certain Clear Eyes drops over sterility concerns, according to a Food and Drug Administration report.

Amylyx Pharmaceuticals, Inc. is upgraded to Strong Buy after positive phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia [PBH]. Avexitide met its primary endpoint, achieving a 55% reduction in severe hypoglycemic events, with strong statistical significance and a favorable safety profile. Key catalysts include an NDA submission for avexitide in PBH by end-2026 and medical data presentation in 2026; expansion into long-acting GLP-1 antagonist AMX0318 is underway.

Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?

Premium Brands TSE: PBH said its revised 2026 outlook reflects timing shifts in U.S. customer programs and the exit of a low-margin Ontario facility, rather than a deterioration in the company's underlying operating assumptions.

California State Teachers Retirement System boosted its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE: PBH) by 21.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 57,310 shares of the company's stock after acquiring an additional 10,117 shares during

Prestige Consumer Healthcare NYSE: PBH reported first-quarter fiscal 2027 revenue growth of 6.5%, supported by broad-based category strength, the initial contribution from its Breathe Right acquisition and retailer order timing. The company raised its reported full-year outlook to incorporate Breathe Right and LaCorium Health while maintaining its prior outlook for organic revenue growth.

Prestige Consumer Healthcare Inc. (PBH) Q1 2027 Earnings Call Transcript

Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $0.95 per share a year ago.

TARRYTOWN, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its first quarter fiscal 2027 ended June 30, 2026.

Bank of New York Mellon Corp cut its position in shares of Prestige Consumer Healthcare Inc. (NYSE: PBH) by 4.2% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned 311,341 shares of the company's stock after selling 13,557 shares during the quarter. Bank